Literature DB >> 11451116

Long-term followup of uncemented tumor endoprostheses for the lower extremity.

F Mittermayer1, P Krepler, M Dominkus, E Schwameis, M Sluga, H Heinzl, R Kotz.   

Abstract

Between 1982 and 1989, 100 primary lower limb reconstructions were done using the Kotz Modular Femur Tibia Reconstruction System after resection of a malignant tumor. In 32 patients a proximal femur prosthesis was implanted, in 40 patients a distal femur prosthesis was implanted, in 19 patients a proximal tibia component was implanted, in four patients a total femur prosthesis was implanted, and in five patients a total knee prosthesis was implanted. The Kaplan-Meier estimate of the overall survival rate of the prostheses was 85% after 3 years, 79% after 5 years, and 71% after 10 years. The most common reason for implant failure was aseptic loosening in 27% of patients (11 patients; range, 10-121 months) after the initial operation. The other reasons for revision surgery were implant fracture (n 5 4) and infection (n 5 4). Early repair of prostheses-related minor complications, such as worn polyethylene bushings, resulted in a statistically significant reduction of implant failure. After a median followup of 127.5 months after the initial surgery, 51 patients had died and eight patients were lost to followup. Forty-one patients were evaluated clinically and radiologically using the Musculoskeletal Tumor Society score and the radiologic implant evaluation system of the International Symposium on Limb Salvage; these 41 patients had a mean of 80% (range, 40%-100%) of the normal functional capability.

Entities:  

Mesh:

Year:  2001        PMID: 11451116     DOI: 10.1097/00003086-200107000-00024

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  69 in total

1.  [Megaprostheses of the knee joint].

Authors:  K Anagnostakos; D Kohn
Journal:  Orthopade       Date:  2010-10       Impact factor: 1.087

2.  [Megaprostheses: KMFTR to GMRS].

Authors:  R Kotz
Journal:  Orthopade       Date:  2010-10       Impact factor: 1.087

Review 3.  Megaprostheses for the treatment of malignant bone tumours of the lower limbs.

Authors:  Christian Heisel; Stefan Kinkel; Ludger Bernd; Volker Ewerbeck
Journal:  Int Orthop       Date:  2006-09-12       Impact factor: 3.075

4.  Oncologic outcome of parosteal osteosarcoma.

Authors:  Manabu Hoshi; Seiichi Matsumoto; Jun Manabe; Taisuke Tanizawa; Toshio Shigemitsu; Naohiro Izawa; Xuedong Shi; Noriyoshi Kawaguchi
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

5.  Influence of stem design on the primary stability of megaprostheses of the proximal femur.

Authors:  Stefan Kinkel; Jan Dennis Graage; Jan Philippe Kretzer; Eike Jakubowitz; Jan Nadorf
Journal:  Int Orthop       Date:  2013-08-18       Impact factor: 3.075

6.  Progress in musculoskeletal oncology from 1922 - 2012.

Authors:  Rainer I Kotz
Journal:  Int Orthop       Date:  2014-05       Impact factor: 3.075

7.  Early equivalence of uncemented press-fit and Compress femoral fixation.

Authors:  German L Farfalli; Patrick J Boland; Carol D Morris; Edward A Athanasian; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2009-06-10       Impact factor: 4.176

8.  What sports activity levels are achieved in patients with modular tumor endoprostheses of osteosarcoma about the knee?

Authors:  Nikolaus W Lang; Gerhard M Hobusch; Philipp T Funovics; Reinhard Windhager; Jochen G Hofstaetter
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

9.  Treatment solutions are unclear for perimegaprosthetic infections.

Authors:  Lisa B Ercolano; Tyson Christensen; Richard McGough; Kurt Weiss
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

10.  Resection arthrodesis for the management of aggressive giant cell tumor of the distal femur.

Authors:  Ayman Abdelaziz Bassiony; Mohamed Abdelrahman; Amr Abdelhady; Mohamed Kamal Assal
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.